Three prescription melanocortin medicines
-
Afamelanotide (Scenesse)
The 1980 linear 13-amino-acid peptide, formulated as a controlled-release subcutaneous rod. EMA's EPAR (last updated October 7, 2026) states: “The European Commission granted a marketing authorisation valid throughout the European Union for Scenesse on 22 December 2014.” FDA's orphan-drug record lists “Marketing Approval Date: 10/08/2019,” and FDA's October 2019 prescribing label states: “SCENESSE is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).”
Read the Scenesse clinical dossier -
Bremelanotide (Vyleesi)
A cyclic heptapeptide with a free acid at the carboxyl terminus (
Read the Vyleesi clinical dossier-OH)—the deaminated derivative of Melanotan II, which ends in an amide group (-NH2). FDA's June 21, 2019 approval letter and June 2019 label state: “VYLEESI is a melanocortin receptor agonist indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance.” The label adds: “VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men.” “VYLEESI is not indicated to enhance sexual performance.” “VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease.” -
Setmelanotide (Imcivree)
A cyclic 8-amino-acid peptide with 20-fold less activity at MC3R and MC1R than at MC4R. FDA's prescribing information (Initial U.S. Approval: 2020; Revised: 03/2026) states: “IMCIVREE is a melanocortin 4 (MC4) receptor agonist indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged (1): 4 years and older with acquired hypothalamic obesity (HO). 2 years and older with Bardet-Biedl syndrome (BBS). 2 years and older with pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).” EMA's EPAR (last updated May 27, 2026) states: “Imcivree received a marketing authorisation valid throughout the EU on 16 July 2021.”
Read the Imcivree clinical dossier